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Abstract
Background: Spontaneous intracerebral hemorrhage (ICH) represents about 15% of all strokes and is associated with high
mortality rates. Our aim was to identify the gene expression changes and biological pathways altered in the brain following
ICH.
Methodology/Principal Findings: Twelve brain samples were obtained from four deceased patients who suffered an ICH
including perihematomal tissue (PH) and the corresponding contralateral white (CW) and grey (CG) matter. Affymetrix
GeneChip platform for analysis of over 47,000 transcripts was conducted. Microarray Analysis Suite 5.0 was used to process
array images and the Ingenuity Pathway Analysis System was used to analyze biological mechanisms and functions of the
genes. We identified 468 genes in the PH areas displaying a different expression pattern with a fold change between 23.74
and +5.16 when compared to the contralateral areas (291 overexpressed and 177 underexpressed). The top genes which
appeared most significantly overexpressed in the PH areas codify for cytokines, chemokines, coagulation factors, cell growth
and proliferation factors while the underexpressed codify for proteins involved in cell cycle or neurotrophins. Validation and
replication studies at gene and protein level in brain samples confirmed microarray results.
Conclusions: The genomic responses identified in this study provide valuable information about potential biomarkers and
target molecules altered in the perihematomal regions.
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Introduction
Spontaneous intracerebral hemorrhage (ICH) is a sudden
devastating form of stroke associated with poor neurological
outcome and high mortality rates. ICH constitutes a major public
health problem with an annual incidence of 10–30 cases per
100,000 population accounting for 2 million strokes worldwide
each year [1]. However, nowadays no satisfactory treatment exists.
Promising clinical trials have recently failed to demonstrate long-
term benefits by preventing hematoma expansion using recombi-
nant activated Factor VII (rFVIIa) [2], although a subset of
younger patients without extensive bleeding at baseline can benefit
from rFVIIa if given within 2.5 hours of symptoms onset [3].
Hence, nowadays excellent medical care given at stroke units is
the only action with potent and direct impact on ICH morbidity
and mortality until a specific therapy is found to treat these
patients [4].
Brain injury after ICH occurs in two phases: a sudden and
initial mass effect of intraparenchymal blood which produces
mechanical disruption of the neurons and glial cells and a
secondary brain injury in surrounding tissue where hematoma
expansion, edema, blood brain barrier disruption, apoptosis and
inflammation can occur. Neuroimaging studies have demonstrated
that hematomas are dynamic and might expand over time
associated with cerebral edema and secondary brain injury. In
this sense it is known that, on average, perihematomal edema
volume increases acutely by approximately 75% during the first
24 hours after ICH [5] and chronically lasts up to day 14 [6].
Thus, to describe genomic changes in the perihematomal areas
could be an interesting approach to identify pathological processes
that occur after ICH and contribute to perihematomal edema and
injury expansion.
Two interesting studies have recently approached the genomic
regulation after ICH by microarray studies [7,8]. First Lu and
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colleagues investigated the brain genomics in a rat model of
intracerebral hemorrhage induced by intrastriatal autologous
blood infusion. Their study focused on the expression patterns
between ICH and non-ICH rats identifying a large number of
genes being regulated in the striatum and the cortical tissue. A
major number of up-regulated genes were directly related to
edema and cellular apoptosis. More recently Carmichael and
colleagues studied by microarray technology the genomic patterns
in acute ICH (,24 hours) compared to healthy brains. In this
study ICH tissue was obtained when adherent tissue to the clot was
incidentally removed during hematoma evacuation in patients
included in the Hemorrhage Evacuation using MR-guided
Endoscopy Surgery—HEME Surgery trial and control tissue
was obtained from autopsy cases that died from cardiopulmonary
arrest. The authors report an upregulation of pro-/anti-inflam-
matoy networks and downregulation of neuronal signaling
pathways.
Our aim was to identify the molecular profiles that contribute to
genomic expression patterns after human spontaneous ICH and to
compare our results with other human studies with similar
approaches. The study has been designed to identify common
expression patterns since patients’ samples from several hours/
days of stroke onset have been studied. Moreover, comparisons
have been done in samples coming from the same individuals
including differences between perihematomal and contralateral
healthy tissues. Finally, a large number of genes has been validated
and also replicated in other ICH cases to confirm consistency and
relevance of our data. We believe that our findings present
potential therapeutic targets and biomarkers for ICH and deserve
further investigation.
Methods
Ethics statement
This study was approved by the Ethics Committee of the Vall
d’Hebron Hospital and informed and written consent was
acquired from all patients or relatives and from controls.
Patients and samples
Brain samples from 4 deceased patients who had a supraten-
torial intracerebral hemorrhage within the previous 4 days were
included in the microarray study. This study group included 2
women and 2 men with a median age of 79 (68–92) years. On
autopsy and during macroscopic exam, perihematomal areas
suspected to present edema were identified by an experienced
neuropathologist using the more recent neuroradiological images
available. Samples from perihematomal areas (PH), contralateral
grey matter (CG) and contralateral white matter (CW) were
obtained within the first 5 hours after death, snap frozen in liquid
nitrogen and stored at 280uC until RNA isolation. For the
replication study four additional patients who had also a
supratentorial intracerebral hemorrhage in the previous 2 days
were selected including 4 men with a median age of 79 (69–90)
years and samples were obtained within the first 18 hours after
death and stored as previously described. Demographic and tissue
sampling data are listed in Table 1.
Additionally, blood samples from 24 hemorrhagic strokes and
20 stroke-free controls at the time of blood sampling were collected
in EDTA tubes and plasma was stored at 280uC for protein
determination. All patients had an acute hypertensive intracere-
bral hemorrhage (ICH) and attended the emergency department
of a teaching hospital. On admission, all patients underwent a
cranial computed tomography (CT) scan and the National
Institute of Health Stroke Scale (NIHSS) score was recorded to
assess neurological status. Blood samples were obtained within the
first 24 hours of stroke symptoms onset and a detailed history of
vascular risk factors was obtained from each patient and control.
Demographic characteristics and risk factors profile are described
in Table 2.
RNA purification and hybridization
RNA was isolated from frozen brain samples using the RNeasyH
kit (Qiagen, Austin, TX, USA). Briefly, approximately 20–40 mg
of frozen tissue was cut from the original piece and purification
was conducted following manufacturers’ instructions. RNaseZAP
was used to clean all surfaces and material. The concentration and
integrity of the total RNA was determined using the Bioanalyzer
2100 platform according to the manufacturers’ protocols (Agilent,
UK). Only RNA with a RIN (RNA integrity number)$5 was used
for the RNA hybridization. An additional cycle of cDNA
synthesizer and amplification was performed to all samples.
Briefly, double-stranded complementary DNA (cDNA) was
synthesized from total purified RNA and biotin-labeled comple-
mentary cRNA was synthesized from cDNA. Finally cRNA was
hybridized to the Affymetrix GeneChip platform for analysis of
over 47,000 transcripts (human U133 Plus 2.0). This was
conducted by the genomics platform core facility of our institution.
All data presented in this study is MIAME compliant and the raw
data have been deposited in a MIAME compliant database, the
NCBI’s Gene Expression Omnibus (GEO), accessible through
GEO Series accession number GSE24265 [9].
Table 1. Demographic and tissue sampling data.
Case Sex Age Time S-E Time E-T Study
27 F 72 12 h 5 h Microarray, Validation and tissue homogenate
28 F 95 39 h 2,5 h Microarray, Validation and tissue homogenate
30 M 67 17 h 3 h Microarray, Validation and tissue homogenate
31 M 86 4 days 4 h Microarray, Validation and tissue homogenate
10 M 92 15 h 5 h Replication and tissue homogenate
11 M 68 18 h 4,5 h Replication and tissue homogenate
17 M 74 2 days 5 h Replication and tissue homogenate
20 M 85 5 h 18 h Replication and tissue homogenate
F, female; M, male; S-E, Stroke to Exitus; E-T, Exitus to Tissue sampling.
doi:10.1371/journal.pone.0016750.t001
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Microarray Analysis
The goal of the study was to compare the gene expression
patterns between perihematomal and contralateral healthy tissue
from the same individuals. Then, to rule out the possibility of
detecting inherent differences between white and grey matter not
influenced by the disease, an indirect comparison was performed
by independently comparing both white and grey matter from the
contralateral hemisphere against the perihematomal tissue and
then comparing white and grey matter between them. Therefore,
3 comparisons of gene expression were calculated per individual:
PH vs. CG, PH vs. CW and CW vs. CG.
The images were processed with the Microarray Analysis Suite
5.0 (Affymetrix, USA). All samples demonstrated characteristics of
high-quality cRNA (39/59 ratio of probe sets for glyceraldehyde-3-
phosphate dehydrogenase and beta-actin of ,1.5) and were
subjected to subsequent analysis. Raw expression values obtained
directly from. CEL files were preprocessed using the RMA
(Robust Multi-Array) method, a three-step process which
integrates background correction, normalization and summariza-
tion of probe values. These normalized values were the basis for all
the analyses. The selection of differentially expressed genes
between conditions was based on a linear model analysis with
empirical Bayes moderation of the variance estimates. In order to
deal with the multiple testing issues derived from the fact that
many tests (one per gene) are performed simultaneously, p-values
were adjusted to obtain strong control over the false discovery rate
(FDR) using the Benjamini and Hochberg method. Array quality
was measured by a series of parameters which are usually provided
by the core facility to confirm that the arrays had been properly
hybridized. To check data quality standard approaches for quality
control were conducted (standard quality controls based on
Affymetrix original methods and Probe-level models) plus
background correction, normalization and filtering. All the
statistical analyses, were done using the free statistical language
R and the libraries developed for microarray data analysis by the
Bioconductor Project (www.bioconductor.org).
A further analysis to identify the biological mechanisms,
pathways and functions and the most relevant genes was
performed using the Ingenuity Pathways Analysis (IPA) software
and database (www.ingenuity.com). Briefly, the dataset containing
gene identifiers and corresponding fold changes was uploaded into
the web-delivered application and each gene identifier was
mapped to its corresponding gene object. The threshold for a
significant association was determined by the –log (0.05),
becoming significant any score above 1.3.
Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR)
A total of 8 patients were studied for gene validation (n = 4) and
replication (n = 4) by qRT-PCR technique (see table 1). Twenty
genes were selected including those that were most up-regulated (IL-
8, CCL20, CXCL5, C15ORF48, SERPINE-1,TFPI2, CD163, CXCL1,
TMEM49) or down-regulated (LHX2, MUM1L1, PRDM16,
NTRK2, PPARGC1A, ERBB4, CRB1, LRRC8B and KCNAB1) in
PH areas and displaying a highlighted role in the functional
pathways analysis. BCAT-1, differentially expressed presenting the
lowest Adj.P.value and GABBR2, identified as a neuronal marker of
grey matter and found up-regulated in our CG areas, were also
included.
Briefly, cDNA synthesis was performed using High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems Inc,
USA). mRNA levels were determined by RT-PCR using a
standard TaqManH PCR kit protocol and TaqMan fluorogenic
probes with a 7500 Real Time PCR System (Applied
Biosystems). The probe location of each particular gene is stated
in table 3 and the Cyclophilin A (PPIA) gene (Hs99999904_m1)
was used as housekeeping gene to normalize the results. All
reactions were run in triplicate on 96-well plates, using a unique
sample as endogenous calibrator control in each one, and
analyzed using the Applied Biosystems SDS 7500 system
software (Applied Biosystems). The RQ values were calculated
by use of the Livak equation: RQ = 22DDCt and the results are
expressed as a ratio depending on the calibrator sample used in
all experiments.
Statistical analysis was conducted using the Statistical Products
and Service Solution (SPSS) package 15.0. Statistical significance
for intergroup differences was assessed by the Mann–Whitney U
and Kruskal–Wallis tests. A p-value lower than 0.05 was
considered statistically significant. Median values and interquartile
range are displayed in box-plot graphs.
IL-8 Enzyme Linked InmunoSorbent Assay
Validation and replication studies were also performed at the
protein level for IL-8. For this purpose the Enzyme Linked
Inmunosorbent Assay (ELISA) kit from Invitrogen (Human IL-8
Ultrasensitive; Camarillo, CA) was used for the in vitro
quantitative determination of IL-8 in human brain tissue
(n = 8) and plasma (n = 20 controls and n = 24 ICH) according
to manufacturer’s instructions. Tissue homogenates were ob-
tained as previously described [10] from the same ICH patients
included in the replication and validation studies that table 1
indicates. Each sample was analyzed twice and the mean of the
two values was used. The mean intra-assay coefficient of
variation of optical densities was lower than 30% for all samples
measured. For tissue samples total protein content of brain
homogenates was determined by the BCA method and equal
amounts (25 micrograms) were assayed and results are expressed
as pg/mL/mg protein. For plasma samples results are expressed
as pg/mL.
Statistical analysis was conducted using the SPSS package
15.0. Statistical significance for intergroup differences was
assessed by the Student t, Mann–Whitney U, and Kruskal–
Wallis tests. A p-value lower than 0.05 was considered
statistically significant. Median values and interquartile range
are displayed in graphs.
Table 2. Demographic features of stroke patients and
healthy volunteers.
Healthy controls
(n =20)
Stroke patients
(n=24) P value
Age (years) 69612 69.2612.7 0.995
Male gender (%) 36.8 62.5 0.095
Smokers (%) 21.1 16.7 0.714
Hypertension (%) 47.4 70.8 0.118
Alcohol (%) 0 16.7 0.069
Diabetes (%) 21.1 4.2 0.074
Dyslipidemia (%) 10.5 12.5 0.841
Coronary artery
disease (%)
15.8 8.4 0.193
Atrial fibrillation (%) 0 20.8 0.039
doi:10.1371/journal.pone.0016750.t002
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Results
Preprocessing and data exploration
One array from the contralateral white matter presented an
unusual performance. After detailed exploration it was removed
before the final analysis was performed (sample 30CW). The
remaining data was properly analyzed using standard techniques.
Briefly, quality control parameters and plots shown in figure S1
indicate that the quality of the arrays was good, including
acceptable and homogenous RNA degradation and signal
distribution and a relatively low background (figure S1A–C).
Once the quality of the data was verified, they were normalized in
order to eliminate systematic biases. Homogeneity of the samples
was analyzed to check if similarities existed between samples of the
same areas (figure S1D). A plot of the first two principal
components from a principal component analysis (PCA) was used
to show the overall structure of the data and we could see how
replicate samples tend to group together, indicating general
similarity in overall expression patterns (figure S1E). At the same
time, hierarchical clustering with Euclidean distance was used to
form the groups based on raw data showing that there was certain
homogeneity since samples from the same areas were grouped into
close clusters (figure S1F).
Transcripts showing differential expression profile
In order to increase statistical power and reduce unnecessary
noise not all genes were analyzed but only those which were
considered to be expressed and showed some variability. This left a
total of 4,136 genes, and of these 3,259 presented significant
differences adjusted by the false discovery rate. Heat maps (color-
coded graphs with samples in columns and genes in rows) were
used to visualize them. Figure 1 illustrates the heat map of
individual gene expression (figure 1A) and of differences between
paired areas (figure 1B) showing that there are groups of co-
regulated genes with a homogeneous expression pattern between
different individuals.
The analysis showed that 359 genes were differentially
expressed in the PH vs. CW group, 2,121 between PH vs. CG
and 2,672 between CW vs. CG areas (adj.P.Val ,0.05 for all
groups), see figure 1C. Significant genes were also graphically
highlighted using the volcano plots which arrange genes along
dimensions of biological and statistical significance (the horizontal
dimension is the fold change between the two groups and the
vertical axis represents the p-value). Then the first axis indicates
biological impact of the change and the second indicates the
statistical evidence of the change, see figure 1D–F.
Importantly, for further analysis all genes showing significant
differences in their expression between CW vs. CG groups were
ruled out since they most likely represent inherent differences in
healthy tissue due to different cellular populations and physiolog-
ical functions (total of 2,672). This indirect comparison allowed us
to discard potential mistakes and indicated that our perihemato-
mal areas were mostly composed by white matter. Indeed, our
results demonstrate that several transcripts reported to be good
neuronal and glial markers of grey and white matter in human
brain samples [11] were found differentially expressed between
CW and CG (see table S1), being potential confounders if not
eliminated from the final list of genes.
Finally, we identified 468 genes in the PH areas displaying a
different expression pattern with a fold change between23.74 and
Table 3. List of selected genes and primers for quantitative RT-PCR.
Gene name LogFC Adj.P.value Primer Studied areas
BCAT-1, branched chain amino-acid transaminase 1 3.45 0.0006 Human BCAT-1 Hs00194075_m1 PH vs. CG and CW
C15ORF48, chromosome 15 open reading frame 48 4.38 0.0046 Human C15ORF48 Hs00260902_m1 PH vs. CG and CW
CCL20, chemokine (C-C motif) ligand 20 4.81 0.0051 Human CCL20 Hs00355476_m1 PH vs. CG
CD163, CD163 molecule 4.16 0.0379 Human CD163 Hs01016661_m1 PH vs. CW
CRB, crumbs homolog 1 22.31 0.0039 Human CRB1 Hs00201372_m1 PH vs. CG
CXCL1, chemokine (C-X-C motif) ligand 1 4.01 0.0037 Human CXCL1 Hs00236937 PH vs. CG and CW
CXCL5, chemokine (C-X-C motif) ligand 5 4.45 0.0346 Human CXCL5 Hs00171085_m1 PH vs. CG and CW
ERBB4, v-erb-a erythroblastic leukemia viral oncogene homolog 4 22.33 0.0098 Human ERBB4 Hs00171783_m1 PH vs. CG
GABBR2, gamma-aminobutyric acid (GABA) B receptor, 2 23.49 0.0028 Human GABBR2 Hs01554998_m1 CW vs. CG
IL-8, Interleukin-8 5.16 0.0084 Human IL-8 Hs99999034_m1 PH vs. CG
KCNAB1, potassium voltage-gated channel, beta member 1 22.20 0.0142 Human KCNAB1 Hs00963155_m1 PH vs. CG
LHX2, LIM homeobox 2 23.74 0.0079 Human LHX2 Hs00180351_m1 PH vs. CG
LRRC8B, leucine rich repeat containing 8 family, member B 22.27 0.0027 Human LRRC8B Hs00372164_m1 PH vs. CG
MUM1L1, melanoma associated antigen (mutated) 1-like 1 22.82 0.0014 Human MUM1L1 Hs00327838_m1 PH vs. CG
NTRK2, neurotrophic tyrosine kinase, receptor, type 2 22.54 0.0049 Human NTRK2 Hs01093103_m1 PH vs. CG
PPARGC1A, peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha
22.38 0.0248 HumanPPARGC1A Hs01016724_m1 PH vs. CG
PRDM16, PR domain containing 16 22.72 0.0134 Human PRDM16 Hs00922674_m1 PH vs. CG
SERPINE1, serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 1
4.32 0.0034 Human SERPINE1 Hs00167155_m1 PH vs. CG and CW
TFPI2, tissue factor pathway inhibitor 2 4.23 0.0484 Human TFPI2 Hs00197918_m1 PH vs. CG and CW
TMEM49, transmembrane protein 49 3.91 0.0072 Human TMEM49 Hs00229548_m1 PH vs. CG and CW
PH (perihematoma), CW (contralateral white) and CG (contralateral grey).
doi:10.1371/journal.pone.0016750.t003
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+5.16 when compared to the contralateral areas (291 were
overexpressed and 177 were underexpressed). Of them, 6.5% of
the genes represented differences between PH vs. CW, 82.5%
between PH vs. CG and 11% between PH and both control areas.
The complete list of genes is published as table S2 with its
corresponding logFold Change and Adj.P.Value.
Pathway and network analysis
Ingenuity Pathways Analysis is a knowledge repository of
networks and biological relationships that has been manually
created from over 200,000 full texts studying approximately
10,000 human genes. For genes with multiple probe sets the one
with the highest logFold Change value was chosen to represent the
gene (differences of expression between different probes were not
significant, data not shown). A total of 468 probe sets representing
the total number of differentially expressed identified genes were
introduced into the IPA system to model and analyze the ontology
pathways: of these 440 were mapped in the system, 134 were
network eligible molecules and 303 were identified in a pathway.
The functional analyses generated through the use of IPA
identified relationships between genes differentially expressed after
ICH in the perihematomal areas in a total of 19 networks. Eight of
these networks were represented with more than 15 molecules
involved with functions related to cell-to-cell signaling and
interaction, antigen presentation, cell-mediated immune response,
immune cell trafficking, cellular growth and proliferation or
humoral immune response. Most relevant network relationships
between molecules are represented in figure 2.
The gene expression pattern led a total of 137 canonical
pathways, 48 of them showing a significant association as seen in
table S3. The most relevant ones were related to cytokines (IL-6,
IL-8, IL-10, IL-17) but also to leukocyte extravasation, TREM-1,
integrin, TGF, p38MAPK or axonal guidance signaling. Within
the large list of genes identified in our study, the IPA analysis
highlighted several genes for being highly up or downregulated
and for being central molecules in the created networks. These
were IL-8, CCL20, CXCL5, C15ORF48, SERPINE1, TFPI2,
CD163, CXCL1 and TMEM49 for up-regulated genes in the
perihematomal areas and FOXG1, LHX2, MUM1L1, PRDM16,
NTRK2, PPARGC1A, ERBB4, CRB1, LRRC8B and KCNAB1 for
downregulated genes in the perihematomal areas. Biofunctions
related to these genes and networks ranked by significance
correspond to cellular growth and proliferation [-log (pva-
lue) = 18.35], cell death [-log (pvalue) = 17.17], cellular develop-
ment [-log (pvalue) = 13.82], cell-to-cell signaling and interaction
[-log (pvalue) = 13.67], cellular movement [-log (pvalue) = 12.97],
tissue development [-log (pvalue) = 12.89], cell morphology [-log
(pvalue) = 12.22] or cell-mediated immune response [-log (pva-
lue) = 9.84] among others.
Validation and replication of microarray data
Our results validate the overexpression patterns identified for
IL-8, CCL20 and SERPINE-1 since gene expression was also
elevated in perihematomal areas by qRT-PCR (p,0.05, see
figure 3A). Although the replication study in a new group of
samples did not show significant differences of these genes they
Figure 1. Raw data from the microarray analysis. A and B) heat maps illustrating gene expression, C) Venn diagram of a total of 3,259 genes
significantly regulated; D, E and F) volcano plots arranging the genes significantly expressed corresponding to the three comparison areas along
dimensions of biological and statistical significance. PH (perihematoma), CW (contralateral white) and CG (contralateral grey).
doi:10.1371/journal.pone.0016750.g001
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were markedly increased in the perihematomal areas compared to
the corresponding contralateral (see figure 3A). Likewise, the same
overexpression pattern was confirmed for CXCL1, CXCL5, TFPI2,
CD163 in both validation and replication studies but not for
BCAT-1, TMEM49 and C15ORF48.
Regarding underexpressed genes most of them showed the same
pattern found in the microarray results (ERRB4, KCNAB1,
PPARGC1A, LHX2 and LRRC8B) as seen in figure 3B. Only the
validation but not the replication study was confirmed for
MUM1L1 and NTRK2. On the other hand, CRB1 and PRDM16
underexpression patterns in the perihematomal areas could not be
confirmed by qRT-PCR as seen in figure 3B.
Finally, the internal control-gene to differentiate between white
and grey matter (GABBR2) confirmed higher expression levels in
grey matter than in white matter (figure 3C).
Validation at the protein level
IL-8 was selected as a candidate gene to be validated at the
protein level for its highlighted role in several functional pathways
and the confirmed validation by qRT-PCR as an overexpressed
gene in the perihematomal area after ICH. Our results confirm
that IL-8 was also overexpressed at the protein level in PH [0.7
(0.16–1.00) pg/mL/mg protein] compared to both CW [0.03
(0.01–0.07) pg/mL/mg protein] and CG [0.06 (0.01–0.43) pg/
mL/mg protein] in tissue homogenates (p = 0.036 and p = 0.046,
respectively), as figure 4A shows. Likewise, IL-8 level was found
elevated in blood samples of acute hemorrhagic stroke patients
compared to healthy subjects [0.43 (0.13–2.61) vs. 0.09 (0.09–1.15)
pg/mL], though not significantly (p = 0.104, figure 4B). Demo-
graphic data and risk factors for patients and controls listed in
Table 2 shows that only atrial fibrillation was significantly more
present in stroke patients than in controls.
Discussion
Our study reports the genes and pathways that are altered after
ICH in perihematomal areas compared to contralateral healthy
tissue in human samples. Overall, our data shows that more than
400 genes display different expression patterns, most of them being
Figure 2. Most relevant molecular networks of interacting genes. The intensity of genes (node) color in the networks indicates the degree of
downregulation (green) or upregulation (red) of gene expression; continuous lines indicate a direct interaction and dashed line an indirect
interaction.
doi:10.1371/journal.pone.0016750.g002
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overexpressed and identified in networks and pathways related to
inflammation and immune response (such as cell-to-cell signaling,
antigen presentation or cell trafficking) but also related to cellular
growth, proliferation or axonal guidance signaling. These results
suggest potential targets to both decrease hematoma expansion
and to potentiate neuroreparative processes beginning in the early
stages of this devastating disease. Finally, some of our findings have
been validated and replicated in other patients at gene and protein
level suggesting also their potential role as ICH biomarkers.
Nowadays microarray studies offer a robust method for the
analysis of whole genome mRNA expression patterns. These
techniques might become a revolution in our understanding of the
molecular mechanisms underlying physiological and pathological
processes and a tool for identifying new targets for treatment.
Several experimental studies have examined the alteration of gene
expression in the postischemic rat brain using microarray
technology [12,13], while in humans both blood and brain
genomic profiling have been investigated after ischemic stroke
[14–17]. Another interesting study from Mitsios and colleagues
investigated the dynamic changes in gene expression in brain
samples following stroke and compared them with those obtained
at similar time points following middle cerebral artery occlusion in
rats [17]. In this study the authors report significant differences in
gene expression profile between human stroke and the animal
model pointing out that an experimental model could not
completely reflect the pathophysiological process of stroke in
humans.
Regarding ICH, a disease with no effective treatment at the
present time, two investigations have used the microarray
technology to study gene expression. Firstly, Lu and colleagues
induced ICH by intrastriatal blood infusion in a rat model
investigating expression patterns compared with saline-injected
animals and more recently Carmichael and colleagues described
the gene pattern profile of human perihematomal tissue of acute
ICH compared with brain tissue of autopsy cases dying from
cardiopulmonary arrest [7,8]. We believe that our study refines the
one published by Carmichael and colleagues since comparisons
are done between perihematomal and contralateral samples of the
same individuals, it provides new data of neuroreparative
processes, it also confirms some of the reported findings and
finally offers a robust validation and replication revision of our
data demonstrating the usefulness of this type of studies to translate
the results at the protein level.
Perihematomal areas have been characterized to suffer edema,
apoptosis, necrosis and inflammatory processes starting early after
the hemorrhagic event, peaking at days 5–6 and involving both
cellular and molecular components [18,19]. In this sense our
functional analysis draws attention to several signaling pathways
responsible for neuroinflammation and related genes such as
TREM-1, IL-8, IL-6, IL1-R1, CXCL2, CXCL5, CCL3, CCL4,
CCL20, VCAM, ICAM or TLR2 among others. These genes have
been found to be overexpressed in perihematomal areas related to
leukocyte extravasation signaling and the explicit presence of
macrophages and monocytes. IL-8 is a chemokine produced
mainly by macrophages and has a pivotal role within these
inflammatory and leukocyte signaling networks. To our knowl-
edge, the only description of IL-8 being overexpressed in
perihematomal brain areas after ICH is the preceding microarray
study in humans [8], although the comparison was done with
control subjects. At the protein level IL-8 has never been described
as a biomarker after ICH in humans. In this regard, we have
previously reported IL-8 serum levels after ischemic stroke [20]
and other authors have shown that patients with ischemic stroke
had high numbers of IL-8 mRNA expressing blood-mononuclear
Figure 4. Validation studies at the protein level. Box-plots show how increased levels of IL-8 were found in perihematoma areas compared to
both contralateral white and grey areas (A) and also in plasma of ICH stroke patients compared to controls (B). *p,0.05.
doi:10.1371/journal.pone.0016750.g004
Figure 3. Complete quantitative RT-PCR validation and replication studies of overexpressed genes (A), underexpressed genes (B)
and control-gene of grey matter (C). Validation study was statistically significant for IL-8, CCL20 and SERPINE-1. Black bars represent PH
(perihematoma), white bars CW (contralateral white) and grey bars CG (contralateral grey). Only the comparisons found differentially expressed in the
main microarray study (as indicated in table 3) are shown here. Expression level is relative to calibrator sample *p,0.05.
doi:10.1371/journal.pone.0016750.g003
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cells correlated with protein plasma level [21] and that high
plasma level of IL-8 during the acute phase of ischemic stroke are
maintained elevated at one week when compared to controls [22].
Interestingly, SERPINE-1 (also known as plasminogen activator
inhibitor type1), SERPINB1 and SERPINB9 that belong to the large
superfamily of serine proteinase inhibitors, have been found
overexpressed in perihematomal areas, and at least SERPINE-1 has
been also validated by quantitative RT-PCR. These proteins may
affect the outcome of ICH since they inhibit serin proteases such as
thrombin or tissue-type plasminogen activator which are known to
exert excitotoxic effects or regulate caspase-mediated apoptosis
[23,24]. In this sense, experimental models of ICH have shown that
SERPINE-1 is increased at gene and protein level around the
hematoma, peaking at the first day and blocked when a specific
thrombin inhibitor such as hirudin was given [25]. The authors
postulate that the up-regulation of plasminogen activator inhibitor-1
may be neuroprotective by limiting thrombin or other serine
protease-induced toxicity. To our knowledge, SERPINB1 and
SERPINB9 have not been studied in the context of ICH or other
neurological diseases. However, the protective role for SERPINB9 is
proved since inhibits TNF-, ligand- and Fas ligand-induced apoptosis
in certain TNF-sensitive cell lines by directly interacting with the
intermediate active forms of caspase-8 and -10 [26]. In this regard,
neuroserpin, another member of the serpin family has been already
tested as an adjuvant therapy for tissue-type plasminogen activator
administration in a rat model of embolic stroke demonstrating
neuroprotective effects [27], but the therapeutic potential of
SERPINE-1, SERPINB1 or SERPINB9 is still unknown.
As mentioned, several regulated genes in the perihematomal
area have been related to brain repair processes such as
neurogenesis, synaptic plasticity or dendrite outgrowth. Endoge-
nous neurogenesis is known to occur under physiologic conditions
in specific areas of the brain such as the subventricular zone of the
lateral ventricle and the subgranular zone of the hippocampal
dentate gyrus [28,29] and after cerebral ischemia in periinfarct
areas [30]. Moreover the presence of potential neural progenitor
cells located in the cerebral cortex has also been reported in post-
stroke murine [31] and human brain [32]. More recently some
studies have reported signs of endogenous neurogenesis in
perihematomal tissue after ICH. Masuda and colleagues have
demonstrated that proliferation in the subventricular zone and
migration towards the hemorrhage areas of neural progenitor cells
occur in a collagenase-induced intracerebral hemorrhage model in
rats [33]. And lately Shen and colleagues have shown that ICH
induces neurogenesis in the adult human brain, since cells
expressing neural stem/progenitor cell-specific markers are
located in perihematomal tissue [34].
Our study proves that several pathways and specific genes
which might direct brain repair processes are highly upregulated
in perihematomal areas. In this regard, TGFb, axonal guidance
and actin cytoskeleton signaling are some of the canonical
pathways identified in our perihematomal areas. The TGFb
superfamily has several subfamilies with numerous members: bone
morphogenetic proteins (which control cell differentiation and
growth), activin/inhibins (with neurotrophic and neuroprotective
effects) and TGFb’s (which control proliferation, cell differentia-
tion and apoptosis) among other molecules. Several important
genes of this superfamily have been found regulated in
perihematomal areas (such as TGFb2, BMP2, INBHA or TGFBI)
and further downstream signaling genes (such as SMAD1)
indicating the potential of modulating these pathways to alter
the damage induced by stroke as others have suggested [35].
Regarding axonal guidance signaling, important genes such as
LINGO-1, expressed in neuronal tissue, part of the Nogo receptor-
complex and responsible for leading the collapse of growth cone
and inhibition of neurite extension [36] has been found down-
regulated in perihematomal areas. The therapeutic potential of
blocking LINGO-1 has been explored in other diseases of the CNS
such as Parkinson’s disease [37] or multiple sclerosis [38]. PFN1,
also named profilin-1, has been found overexpressed in our study.
This gene encodes for an actin-binding protein essential for
neuronal differentiation and synaptic plasticity [39] but whether or
no it plays an important role in neurogenesis and tissue repair after
stroke still needs to be elucidated. Another example of an up-
regulated gene in perihematomal tissue and potentially related
with endogenous repair mechanisms is CDC42, a small GTPase of
the Rho-subfamily. This gene is a key regulator of morphological
changes in neurons responsible for dendrite outgrowth thorough
dendritic cytoskeletal organization [40]. Although there are no
human studies in both ICH and ischemic stroke, an experimental
study in rats shows how gene therapy with hepatocyte growth
factor improved significantly learning and memory during the
recovery phase of stroke related to an increase of CDC42 positive
pyramidal neurons in the periinfarct areas and enhanced
neuritogenesis [41].
Clearly it is difficult to analyze and describe the role of the
complete list of genes reported in this type of studies. We have
focused our validation and replication studies on the genes that were
particularly over- or underexpressed and that represent key
molecules in the canonical pathways or functional networks modeled
by the IPA system. However, we recognize that other genes might be
of great interest too. In this regard, several genes involved in the
inflammatory/anti-inflammatory networks described by Carmichael
and colleagues [8] are also induced in our study (such as CXCL2,
CXCL3, IL1R1 or ANXA2, TGFBI, respectively). More specifically,
64 (13.67%) out of the 468 identified genes were also reported in this
other study. Of these, 47 (73.43%) were underexpressed in both
studies, 15 (23.43%) were up-regulated and only 2 (3.12%) showed
divergences. Another drawback is that genes playing a central role in
some of the identified pathways could not be found altered in the
perihematomal areas in our study probably because the expression
levels were not high or stable enough to be considered differentially
expressed. This is the case of TNF which is known to be present in
the brain after induced-ICH [42] or MMP9, known to be present in
perihematomal areas in humans [10] and to be altered in blood
related to early hematoma expansion [43] and perihematomal
edema [44]. We recognize that some contamination from peripheral
blood exists in our samples since brain perfusion to remove blood
from brain vessels was not possible. However, we believe that this
technical limitation might not be influencing our final results since
comparisons have been performed with contralateral tissue of the
same individuals. Finally, apparent differences in gender, alcohol
consumption and presence of atrial fibrillation exist between controls
and strokes in our protein study at blood level, and this could
interfere with the interpretation of the results.
In conclusion, our study provides novel information with
rigorous bioinformatic approaches, validation and replication data
about genes and pathways that might be responsible for
perihematomal secondary injury but also of endogenous repair
mechanisms becoming targets of therapeutic interest.
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